| scholarly article | Q13442814 |
| P50 | author | Yasumasa Yoshiyama | Q56839678 |
| Tetsuya Suhara | Q114244127 | ||
| John Q. Trojanowski | Q6253636 | ||
| P2093 | author name string | Bin Zhang | |
| Virginia M-Y Lee | |||
| Jun Maeda | |||
| Makoto Higuchi | |||
| Takaomi C Saido | |||
| Nobuhisa Iwata | |||
| Shu-Ming Huang | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microtubule associated protein tau | Q419507 |
| microglia | Q1622829 | ||
| synapse organization | Q14862256 | ||
| tauopathy | Q2397106 | ||
| P304 | page(s) | 337-351 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Neuron | Q3338676 |
| P1476 | title | Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model | |
| P478 | volume | 53 |
| Q64234968 | 15-Deoxy-Δ-prostaglandin J2 promotes phosphorylation of eukaryotic initiation factor 2α and activates the integrated stress response |
| Q27334236 | 3D Visualization of the Temporal and Spatial Spread of Tau Pathology Reveals Extensive Sites of Tau Accumulation Associated with Neuronal Loss and Recognition Memory Deficit in Aged Tau Transgenic Mice |
| Q57927766 | A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease |
| Q90999408 | A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice |
| Q58599310 | A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model |
| Q37615169 | A clear and present danger: endogenous ligands of Toll-like receptors |
| Q28743487 | A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice |
| Q37499825 | A lifespan observation of a novel mouse model: in vivo evidence supports aβ oligomer hypothesis |
| Q37625372 | A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease |
| Q37273007 | A rapid gene delivery-based mouse model for early-stage Alzheimer disease-type tauopathy |
| Q46070173 | A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice |
| Q89983604 | A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals |
| Q90205445 | A unique tau conformation generated by an acetylation-mimic substitution modulates P301S-dependent tau pathology and hyperphosphorylation |
| Q40239437 | AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy |
| Q50420723 | AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy |
| Q36941624 | AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo |
| Q47836602 | AMPA Receptor Trafficking in Natural and Pathological Aging |
| Q35006687 | Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies |
| Q36591506 | Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss |
| Q89624658 | Absence of microglia or presence of peripherally-derived macrophages does not affect tau pathology in young or old hTau mice |
| Q41981479 | Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1. |
| Q36877497 | Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss |
| Q39085129 | Acetylated tau in Alzheimer's disease: An instigator of synaptic dysfunction underlying memory loss: Increased levels of acetylated tau blocks the postsynaptic signaling required for plasticity and promotes memory deficits associated with tauopathy |
| Q33703231 | Acetylation of tau inhibits its degradation and contributes to tauopathy |
| Q91852975 | Activated CX3CL1/Smad2 Signals Prevent Neuronal Loss and Alzheimer's Tau Pathology-Mediated Cognitive Dysfunction |
| Q64060265 | Activated cofilin exacerbates tau pathology by impairing tau-mediated microtubule dynamics |
| Q33724546 | Activated microglia do not form functional gap junctions in vivo |
| Q48232371 | Active Immunization with DNA Vaccine Reduced Cerebral Inflammation and Improved Cognitive Ability in APP/PS1 Transgenic Mice by In Vivo Electroporation |
| Q36286130 | Active zone proteins are transported via distinct mechanisms regulated by Par-1 kinase |
| Q92324290 | Activity-Dependent Reconnection of Adult-Born Dentate Granule Cells in a Mouse Model of Frontotemporal Dementia |
| Q36316228 | Administration of NaHS Attenuates Footshock-Induced Pathologies and Emotional and Cognitive Dysfunction in Triple Transgenic Alzheimer's Mice |
| Q42163915 | Age-dependent effects of microglial inhibition in vivo on Alzheimer's disease neuropathology using bioactive-conjugated iron oxide nanoparticles |
| Q27317039 | Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD. |
| Q64273642 | Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo |
| Q98288848 | Aging Alters Olfactory Bulb Network Oscillations and Connectivity: Relevance for Aging-Related Neurodegeneration Studies |
| Q33955075 | Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration. |
| Q64277005 | Altered brain arginine metabolism in a mouse model of tauopathy |
| Q27302961 | Altered brain energetics induces mitochondrial fission arrest in Alzheimer's Disease |
| Q37681990 | Altered sleep and EEG power in the P301S Tau transgenic mouse model |
| Q91781242 | Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species |
| Q85013370 | Alzheimer disease |
| Q37180666 | Alzheimer disease pathology as a host response |
| Q55353865 | Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits. |
| Q26778149 | Alzheimer's Disease: Mechanism and Approach to Cell Therapy |
| Q41592614 | Alzheimer's disease pathological lesions activate the spleen tyrosine kinase |
| Q89841160 | Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How |
| Q48262702 | Alzheimer's disease-like pathology induced by amyloid-β oligomers in nonhuman primates. |
| Q39057135 | Alzheimer's disease: experimental models and reality |
| Q89962342 | Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein |
| Q38122150 | Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins |
| Q30387426 | Ameliorative Effects of Antioxidants on the Hippocampal Accumulation of Pathologic Tau in a Rat Model of Blast-Induced Traumatic Brain Injury |
| Q36040886 | Amyloid deposition and advanced age fails to induce Alzheimer's type progression in a double knock-in mouse model |
| Q39420600 | Amyloid precursor protein and tau transgenic models of Alzheimer‘s disease: insights from the past and directions for the future |
| Q46240783 | Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies. |
| Q104103819 | Amyloid-β impairs the phagocytosis of dystrophic synapses by astrocytes in Alzheimer's disease |
| Q101165800 | An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline |
| Q42933005 | An engulfment assay: a protocol to assess interactions between CNS phagocytes and neurons |
| Q41866952 | An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide |
| Q42117797 | Analysis of in vivo turnover of tau in a mouse model of tauopathy |
| Q47272117 | Analysis of the vasculature by immunohistochemistry in paraffin-embedded brains |
| Q28087158 | Analyzing dendritic spine pathology in Alzheimer's disease: problems and opportunities |
| Q37196122 | Animal models of Alzheimer's disease and frontotemporal dementia |
| Q41854166 | Anti-inflammatory impact of minocycline in a mouse model of tauopathy. |
| Q41955482 | Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. |
| Q38829673 | Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy |
| Q41150186 | Anti-tau antibody reduces insoluble tau and decreases brain atrophy |
| Q51731158 | Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice. |
| Q39391538 | Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases |
| Q47344432 | Antisense oligonucleotides: the next frontier for treatment of neurological disorders |
| Q46160288 | ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy |
| Q90410725 | Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer's Disease |
| Q36073366 | Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis |
| Q37220627 | Assessment of neuroinflammation in a mouse model of obesity and β-amyloidosis using PET. |
| Q30621402 | Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory |
| Q35164566 | Attenuation of microglial activation in a mouse model of Alzheimer's disease via NFAT inhibition |
| Q41356153 | Automated quantification of neuronal networks and single-cell calcium dynamics using calcium imaging. |
| Q38020618 | Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. |
| Q34162478 | A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model |
| Q58710855 | BDNF inhibits neurodegenerative disease-associated asparaginyl endopeptidase activity via phosphorylation by AKT |
| Q91529261 | BIN1 favors the spreading of Tau via extracellular vesicles |
| Q35496991 | Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice |
| Q35756089 | Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice |
| Q124094901 | Behavioural Functions and Cerebral Blood Flow in a P301S Tauopathy Mouse Model: A Time-Course Study |
| Q37869409 | Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathies |
| Q88961378 | Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy |
| Q64018601 | Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. |
| Q28273620 | Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice |
| Q41059274 | Bidirectional interplay of HSF1 degradation and UPR activation promotes tau hyperphosphorylation |
| Q38936788 | Bioassays and Inactivation of Prions |
| Q34572900 | Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease |
| Q96129239 | Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer's and Parkinson's diseases |
| Q37611380 | Blast exposure causes dynamic microglial/macrophage responses and microdomains of brain microvessel dysfunction |
| Q34996880 | Blocking Effects of Human Tau on Squid Giant Synapse Transmission and Its Prevention by T-817 MA. |
| Q33810933 | Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model |
| Q47438369 | Brain 5-lipoxygenase over-expression worsens memory, synaptic integrity, and tau pathology in the P301S mice |
| Q34286417 | Brain diabetic neurodegeneration segregates with low intrinsic aerobic capacity |
| Q36915421 | Brain homogenates from human tauopathies induce tau inclusions in mouse brain |
| Q26861683 | Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies |
| Q33951935 | Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies |
| Q37893588 | Brief update on different roles of tau in neurodegeneration |
| Q37633222 | CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. |
| Q37446027 | CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. |
| Q35747152 | CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy |
| Q35213298 | CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. |
| Q90429677 | Ca2+, Astrocyte Activation and Calcineurin/NFAT Signaling in Age-Related Neurodegenerative Diseases |
| Q46467885 | Caspase-2 cleavage of tau reversibly impairs memory |
| Q36943100 | Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease |
| Q92593057 | Cell-autonomous and non-cell autonomous effects of neuronal BIN1 loss in vivo |
| Q38185934 | Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases |
| Q96816564 | Cellular senescence and Alzheimer disease: the egg and the chicken scenario |
| Q58758080 | Cellular senescence, geroscience, cancer and beyond |
| Q88488990 | Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology |
| Q56972630 | Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia |
| Q92638553 | Changes in visual function and retinal structure in the progression of Alzheimer's disease |
| Q41786144 | Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention |
| Q36446135 | Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain |
| Q36852550 | Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies |
| Q34500234 | Characterization of tau oligomeric seeds in progressive supranuclear palsy |
| Q33771643 | Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue |
| Q124094957 | Chemical Stimulation of Rodent and Human Cortical Synaptosomes: Implications in Neurodegeneration |
| Q99585434 | Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer's disease and frontotemporal lobar degeneration |
| Q57464033 | Chronic Sleep Disruption Advances the Temporal Progression of Tauopathy in P301S Mutant Mice |
| Q35046682 | Chronic Stimulation of Alpha-2A-Adrenoceptors With Guanfacine Protects Rodent Prefrontal Cortex Dendritic Spines and Cognition From the Effects of Chronic Stress |
| Q37721865 | Chronic Traumatic Encephalopathy: The Neuropathological Legacy of Traumatic Brain Injury |
| Q89547106 | Chronic White Matter Degeneration, but No Tau Pathology at One-Year Post-Repetitive Mild Traumatic Brain Injury in a Tau Transgenic Model |
| Q38749513 | Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wild-type and MAPT transgenic mice. |
| Q55505826 | Chronic stress as a risk factor for Alzheimer's disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress. |
| Q35590867 | Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy |
| Q47887763 | Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology |
| Q59086809 | Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline |
| Q34473854 | Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. |
| Q42280027 | Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. |
| Q99711214 | Commentary: Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model |
| Q45399830 | Compensating for synaptic loss in Alzheimer's disease |
| Q92984481 | Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer's Disease |
| Q38045262 | Concise review: Can stem cells be used to treat or model Alzheimer's disease? |
| Q36016920 | Conditional deletion of Notch1 and Notch2 genes in excitatory neurons of postnatal forebrain does not cause neurodegeneration or reduction of Notch mRNAs and proteins |
| Q27314989 | Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits |
| Q90136807 | Cross species application of quantitative neuropathology assays developed for clinical Alzheimer's disease samples |
| Q64249418 | Crosstalk between Oxidative Stress and Tauopathy |
| Q60310921 | Current state of Alzheimer's fluid biomarkers |
| Q37092476 | Debris clearance by microglia: an essential link between degeneration and regeneration. |
| Q57029721 | Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease |
| Q36437437 | Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice |
| Q48144215 | Dendritic pathology in prion disease starts at the synaptic spine. |
| Q34910148 | Dendritic spine instability leads to progressive neocortical spine loss in a mouse model of Huntington's disease. |
| Q27311815 | Depletion of microglia and inhibition of exosome synthesis halt tau propagation |
| Q50132697 | Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. |
| Q37122807 | Dietary and donepezil modulation of mTOR signaling and neuroinflammation in the brain. |
| Q30412009 | Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration |
| Q38322767 | Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases |
| Q57049896 | Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy |
| Q35009550 | Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains |
| Q37266516 | Differential progression of structural and functional alterations in distinct retinal ganglion cell types in a mouse model of glaucoma |
| Q40240888 | Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo. |
| Q56889147 | Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau |
| Q59328931 | Distinct Microglial Responses in Two Transgenic Murine Models of TAU Pathology |
| Q41904960 | Distinct tau prion strains propagate in cells and mice and define different tauopathies |
| Q28293967 | Distinct α-synuclein strains differentially promote tau inclusions in neurons |
| Q35826638 | Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation |
| Q34610331 | Drosophila models of neurodegenerative diseases |
| Q39217121 | Dynamics of the Complement, Cytokine, and Chemokine Systems in the Regulation of Synaptic Function and Dysfunction Relevant to Alzheimer's Disease |
| Q38875190 | Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer's Disease |
| Q46121276 | Dysregulation of PINCH signaling in mesial temporal epilepsy |
| Q92242499 | Dysregulation of RNA Splicing in Tauopathies |
| Q34519947 | Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice |
| Q91725089 | Early Electrophysiological Disintegration of Hippocampal Neural Networks in a Novel Locus Coeruleus Tau-Seeding Mouse Model of Alzheimer's Disease |
| Q30836664 | Early and progressive deficit of neuronal activity patterns in a model of local amyloid pathology in mouse prefrontal cortex |
| Q30480000 | Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice |
| Q34602175 | Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy |
| Q53416720 | Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy. |
| Q30587345 | Early microglia activation in a mouse model of chronic glaucoma |
| Q34405368 | Early reduction of microglia activation by irradiation in a model of chronic glaucoma |
| Q92999264 | Ectopic Expression Induces Abnormal Somatodendritic Distribution of Tau in the Mouse Brain |
| Q37859076 | Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease |
| Q33300947 | Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation |
| Q90441714 | Ellagic acid ameliorates learning and memory impairment in APP/PS1 transgenic mice via inhibition of β-amyloid production and tau hyperphosphorylation |
| Q57491513 | Elucidating the Interactive Roles of Glia in Alzheimer's Disease Using Established and Newly Developed Experimental Models |
| Q45870549 | Emerging Diagnostic and Therapeutic Strategies for Tauopathies |
| Q90454180 | Emerging Roles of Astrocytes in Neuro-Vascular Unit and the Tripartite Synapse With Emphasis on Reactive Gliosis in the Context of Alzheimer's Disease |
| Q47234302 | Endoplasmic reticulum stress responses in mouse models of Alzheimer disease: overexpression paradigm versus knock-in paradigm |
| Q47670971 | Enhanced tau pathology via RanBP9 and Hsp90/Hsc70 chaperone complexes. |
| Q92856694 | Entanglement of CCR5 and Alzheimer's Disease |
| Q64947677 | Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer's human brains. |
| Q34218584 | Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy |
| Q41240654 | Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy |
| Q37525481 | Evidence of Tau Hyperphosphorylation and Dystrophic Microglia in the Common Marmoset |
| Q37238270 | Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments |
| Q28395854 | Examining the relationship between head trauma and neurodegenerative disease: A review of epidemiology, pathology and neuroimaging techniques |
| Q64067761 | Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease |
| Q43149202 | Exploring human/animal intersections: converging lines of evidence in comparative models of aging |
| Q49830067 | Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD. |
| Q89497605 | Exposure to 3-Nitropropionic Acid Mitochondrial Toxin Induces Tau Pathology in Tangle-Mouse Model and in Wild Type-Mice |
| Q36759553 | Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice |
| Q33819121 | Expression of P301L-hTau in mouse MEC induces hippocampus-dependent memory deficit |
| Q42288828 | Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis |
| Q35022620 | Expression of Tau40 induces activation of cultured rat microglial cells |
| Q42371467 | Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies |
| Q50878634 | FK506 reduces abnormal prion protein through the activation of autolysosomal degradation and prolongs survival in prion-infected mice. |
| Q48585121 | FOXP2 Expression in Frontotemporal Lobar Degeneration-Tau. |
| Q41820128 | Formation and propagation of tau oligomeric seeds |
| Q90230828 | Formulated Chinese Medicine Shaoyao Gancao Tang Reduces Tau Aggregation and Exerts Neuroprotection through Anti-Oxidation and Anti-Inflammation |
| Q38037524 | Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases |
| Q38625515 | Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies |
| Q38050217 | Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development |
| Q35737271 | Frontotemporal lobar degeneration-related proteins induce only subtle memory-related deficits when bilaterally overexpressed in the dorsal hippocampus |
| Q38659874 | Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology |
| Q47839014 | Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. |
| Q37451385 | Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. |
| Q26748713 | Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease |
| Q26747585 | Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats |
| Q38306065 | Further understanding of tau phosphorylation: implications for therapy. |
| Q47582501 | G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. |
| Q47684773 | GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils. |
| Q42631490 | Gamma frequency entrainment attenuates amyloid load and modifies microglia |
| Q36524290 | Gene Therapy Models of Alzheimer's Disease and Other Dementias |
| Q89919455 | Generation and Characterization of Novel Monoclonal Antibodies Targeting p62/sequestosome-1 Across Human Neurodegenerative Diseases |
| Q41196178 | Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. |
| Q92535576 | Genetic Background Influences the Propagation of Tau Pathology in Transgenic Rodent Models of Tauopathy |
| Q34497123 | Genetic rodent models of amyotrophic lateral sclerosis |
| Q33847602 | Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies |
| Q64985120 | Genetically Engineered iPSC-Derived FTDP-17 MAPT Neurons Display Mutation-Specific Neurodegenerative and Neurodevelopmental Phenotypes. |
| Q60044492 | Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model |
| Q32173558 | Glial contributions to neurodegeneration in tauopathies |
| Q55345450 | Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia. |
| Q36680395 | Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo |
| Q92402771 | Hibernation Impairs Odor Discrimination - Implications for Alzheimer's Disease |
| Q37480434 | Hippocampal 'zipper' slice studies reveal a necessary role for calcineurin in the increased activity of L-type Ca(2+) channels with aging |
| Q39210948 | Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy |
| Q90050046 | Hippocampal tau oligomerization early in tau pathology coincides with a transient alteration of mitochondrial homeostasis and DNA repair in a mouse model of tauopathy |
| Q44199130 | Homeostatic responses by surviving cortical pyramidal cells in neurodegenerative tauopathy |
| Q36490240 | Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss |
| Q35986968 | Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction |
| Q57816597 | Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability |
| Q42555418 | Hyperphosphorylation-induced tau oligomers |
| Q30543829 | Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH |
| Q34253841 | Identification and characterization of triamcinolone acetonide, a microglial-activation inhibitor |
| Q63988407 | Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia |
| Q33713341 | Identification of oligomers at early stages of tau aggregation in Alzheimer's disease |
| Q26770766 | Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging |
| Q24642726 | Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies |
| Q37259426 | Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls |
| Q55401909 | Imbalanced Expression of Tau and Tubulin Induces Neuronal Dysfunction in C. elegans Models of Tauopathy. |
| Q93158341 | Immune Signaling in Neurodegeneration |
| Q34213029 | Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis |
| Q50961266 | Immunomodulation of memory-impairing protein tau in Alzheimer's disease. |
| Q37655247 | Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. |
| Q35104249 | Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model |
| Q37308949 | Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. |
| Q41849339 | Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice |
| Q33678309 | In Silico Insight into Potent of Anthocyanin Regulation of FKBP52 to Prevent Alzheimer's Disease. |
| Q35890404 | In Vivo Differences between Two Optical Isomers of Radioiodinated o-iodo-trans-decalinvesamicol for Use as a Radioligand for the Vesicular Acetylcholine Transporter |
| Q47865475 | In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510. |
| Q90399853 | In vivo Bioluminescence Imaging Used to Monitor Disease Activity and Therapeutic Response in a Mouse Model of Tauopathy |
| Q58588635 | In vivo Molecular Imaging of Neuroinflammation in Alzheimer's disease |
| Q36630863 | In vivo functional brain mapping in a conditional mouse model of human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures |
| Q35002449 | In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy |
| Q34985153 | In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice |
| Q35654128 | In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders |
| Q48314517 | In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. |
| Q45969642 | Increased association between rough endoplasmic reticulum membranes and mitochondria in transgenic mice that express P301L tau. |
| Q40911563 | Increased calcineurin expression after pilocarpine-induced status epilepticus is associated with brain focal edema and astrogliosis |
| Q38626337 | Increased hippocampal CA1 density of serotonergic terminals in a triple transgenic mouse model of Alzheimer's disease: an ultrastructural study |
| Q34590082 | Increased tau phosphorylation and tau truncation, and decreased synaptophysin levels in mutant BRI2/tau transgenic mice |
| Q37031576 | Increased tauopathy drives microglia-mediated clearance of beta-amyloid. |
| Q24681736 | Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice |
| Q34325388 | Inflammation and white matter degeneration persist for years after a single traumatic brain injury |
| Q38891157 | Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models |
| Q37912590 | Inflammation in the early stages of neurodegenerative pathology |
| Q35071072 | Inflammation induced by infection potentiates tau pathological features in transgenic mice |
| Q58700943 | Inflammation: the link between comorbidities, genetics, and Alzheimer's disease |
| Q46546882 | Inhibition of Endocannabinoid Degradation Improves Outcomes from Mild Traumatic Brain Injury: A Mechanistic Role for Synaptic Hyperexcitability |
| Q30358929 | Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease. |
| Q47799595 | Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia |
| Q42202910 | Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. |
| Q38223011 | Innate immune activation in neurodegenerative disease |
| Q38358574 | Innate immunity in Alzheimer's disease |
| Q39314130 | Innate immunity in Alzheimer's disease: the relevance of animal models? |
| Q42118844 | Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology. |
| Q38191590 | Insulin dysfunction and Tau pathology. |
| Q57039694 | Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau |
| Q37969262 | Interaction between pathogenic proteins in neurodegenerative disorders |
| Q53324250 | Interaction between α-synuclein and other proteins in neurodegenerative disorders. |
| Q37195010 | Interactions between APP secretases and inflammatory mediators |
| Q36808464 | Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. |
| Q35816898 | Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. |
| Q91114669 | Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight |
| Q91660737 | Intersection of pathological tau and microglia at the synapse |
| Q26747203 | Intracellular Calcium Dysregulation: Implications for Alzheimer's Disease |
| Q43116153 | Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice |
| Q35055486 | Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration |
| Q41117629 | Introducing directly induced microglia-like (iMG) cells from fresh human monocytes: a novel translational research tool for psychiatric disorders |
| Q90286851 | Introduction of Tau Oligomers into Cortical Neurons Alters Action Potential Dynamics and Disrupts Synaptic Transmission and Plasticity |
| Q38271896 | Invited review: Animal models of tauopathies and their implications for research/translation into the clinic |
| Q38569669 | Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents. |
| Q35137455 | Isolation and characterization of antibody fragments selective for toxic oligomeric tau |
| Q46689694 | Kinetics of Human Mutant Tau Prion Formation in the Brains of 2 Transgenic Mouse Lines |
| Q92515239 | Knock-in of Mutated hTAU Causes Insulin Resistance, Inflammation and Proteostasis Disturbance in a Mouse Model of Frontotemporal Dementia |
| Q36859244 | Knock-out and transgenic mouse models of tauopathies. |
| Q42171235 | LSD1 protects against hippocampal and cortical neurodegeneration |
| Q48264748 | Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau. |
| Q92348553 | Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau |
| Q41159842 | Lessons Learned about Neurodegeneration from Microglia and Monocyte Depletion Studies |
| Q33668480 | Ligand-based and structure-based investigation for Alzheimer's disease from traditional chinese medicine |
| Q96136111 | Liquid-liquid phase separation induces pathogenic tau conformations in vitro |
| Q47580999 | Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice |
| Q53448459 | Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease. |
| Q89963823 | Long Term Gene Expression in Human Induced Pluripotent Stem Cells and Cerebral Organoids to Model a Neurodegenerative Disease |
| Q34794030 | Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice |
| Q40415700 | Longitudinal imaging reveals subhippocampal dynamics in glutamate levels associated with histopathologic events in a mouse model of tauopathy and healthy mice |
| Q46956780 | Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography |
| Q30494776 | Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis |
| Q47763484 | Loss of synaptophysin immunoexpression in primary progressive aphasia |
| Q41590526 | Loss of tau rescues inflammation-mediated neurodegeneration |
| Q48711898 | Low-dose total-body carbon-ion irradiations induce early transcriptional alteration without late Alzheimer's disease-like pathogenesis and memory impairment in mice |
| Q46620006 | MRNA Levels of ACh-Related Enzymes in the Hippocampus of THY-Tau22 Mouse: A Model of Human Tauopathy with No Signs of Motor Disturbance. |
| Q34125535 | MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology |
| Q38506602 | Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging |
| Q34878224 | Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition |
| Q33859830 | Mechanisms of tau-induced neurodegeneration |
| Q37630546 | Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease |
| Q37043326 | Membrane trafficking in neuronal maintenance and degeneration. |
| Q33784466 | Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity |
| Q89459080 | MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways |
| Q35708750 | Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. |
| Q46461757 | Microglia and macrophages in brain homeostasis and disease |
| Q38176000 | Microglia and synapse: interactions in health and neurodegeneration |
| Q90705375 | Microglia changes associated to Alzheimer's disease pathology in aged chimpanzees |
| Q42911754 | Microglia display modest phagocytic capacity for extracellular tau oligomers |
| Q41014561 | Microglia function in Alzheimer's disease |
| Q57490199 | Microglia in Alzheimer's Disease: A Role for Ion Channels |
| Q56922819 | Microglia in Alzheimer's disease |
| Q60949648 | Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response |
| Q91786444 | Microglia in neurodegeneration |
| Q42038294 | Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease. |
| Q35606301 | Microglia: scapegoat, saboteur, or something else? |
| Q34587134 | Microglial P2X₇ receptor expression is accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse model of Alzheimer's disease |
| Q26739495 | Microglial Priming and Alzheimer's Disease: A Possible Role for (Early) Immune Challenges and Epigenetics? |
| Q37424545 | Microglial derived tumor necrosis factor-α drives Alzheimer's disease-related neuronal cell cycle events |
| Q36348184 | Microglial malfunction: the third rail in the development of Alzheimer's disease |
| Q92229463 | Microglial microRNAs mediate sex-specific responses to tau pathology |
| Q55358469 | Microglial priming in Alzheimer's disease. |
| Q38047388 | Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies |
| Q39206398 | Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease |
| Q34631209 | Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism |
| Q99616984 | Modulating TRADD to restore cellular homeostasis and inhibit apoptosis |
| Q38138991 | Modulation of adult-born neurons in the inflamed hippocampus. |
| Q38184606 | Modulation of inflammation in transgenic models of Alzheimer's disease |
| Q60046676 | Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia |
| Q38019956 | Molecular imaging of dementia. |
| Q37462278 | Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches |
| Q26829009 | Mouse models of frontotemporal dementia |
| Q92419403 | Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition |
| Q39119194 | Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition |
| Q37752915 | Murine models of Alzheimer's disease and their use in developing immunotherapies. |
| Q38545158 | Mutations in MAPT give rise to aneuploidy in animal models of tauopathy |
| Q40060551 | NFATs and Alzheimer's Disease. |
| Q42656183 | NPT088 reduces both amyloid-β and tau pathologies in transgenic mice |
| Q41512953 | NSAIDs: How they Work and their Prospects as Therapeutics in Alzheimer's Disease |
| Q90699208 | Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice |
| Q39144600 | Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support. |
| Q38966578 | Neurodegeneration Enhances the Development of Arthritis. |
| Q39134078 | Neurodegenerative Disease Transmission and Transgenesis in Mice. |
| Q36918222 | Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing mutant tau. |
| Q38681542 | Neuroimaging and its Relevance to Understanding Pathways Linking Diabetes and Cognitive Dysfunction. |
| Q52344625 | Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration. |
| Q34933261 | Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration |
| Q90373014 | Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum |
| Q90399950 | Neuroinflammation as a Common Feature of Neurodegenerative Disorders |
| Q38126949 | Neuroinflammation in Alzheimer's disease: an understanding of physiology and pathology |
| Q64933464 | Neuroinflammation in mouse models of Alzheimer's disease. |
| Q46671150 | Neuroinflammatory Gene Regulation, Mitochondrial Function, Oxidative Stress, and Brain Lipid Modifications With Disease Progression in Tau P301S Transgenic Mice as a Model of Frontotemporal Lobar Degeneration-Tau |
| Q35949689 | Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. |
| Q37780959 | Neuronal models for studying tau pathology. |
| Q49077271 | Neuropathologic classification of dementias: introduction |
| Q27003314 | Neuropathological alterations in Alzheimer disease |
| Q92580591 | Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy |
| Q37319294 | New approaches to the treatment of frontotemporal lobar degeneration |
| Q36600358 | New directions for frontotemporal dementia drug discovery |
| Q36966038 | Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy |
| Q38974344 | Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. |
| Q90724248 | Noninvasive 40-Hz light flicker to recruit microglia and reduce amyloid beta load |
| Q92725736 | Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology |
| Q54979137 | Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase. |
| Q94450921 | Novel alterations in corneal neuroimmune phenotypes in mice with central nervous system tauopathy |
| Q52613291 | Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. |
| Q34416323 | Organotypic brain slice cultures of adult transgenic P301S mice--a model for tauopathy studies |
| Q47412565 | Overexpression of 5-Lipoxygenase Worsens the Phenotype of a Mouse Model of Tauopathy |
| Q90162258 | Overview of Transgenic Mouse Models for Alzheimer's Disease |
| Q37101305 | Oxidative stress and the pathogenesis of Alzheimer's disease |
| Q87512835 | Oxidative stress in Alzheimer's disease |
| Q98564405 | P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice |
| Q30475074 | P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating |
| Q45951320 | PENN neurodegenerative disease research - in the spirit of Benjamin Franklin. |
| Q34647958 | PINCH in the cellular stress response to tau-hyperphosphorylation |
| Q90286842 | PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment |
| Q124094891 | PSA-NCAM Regulatory Gene Expression Changes in the Alzheimer’s Disease Entorhinal Cortex Revealed with Multiplexed in situ Hybridization |
| Q38690404 | Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis |
| Q36596241 | Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6). |
| Q50856591 | Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. |
| Q27308146 | Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models |
| Q99585475 | Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer's disease models |
| Q35204878 | Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice |
| Q26850298 | Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders |
| Q41654374 | Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies. |
| Q34481921 | Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease |
| Q34044073 | Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old |
| Q52140489 | Persistence of intact retinal ganglion cell terminals after axonal transport loss in the DBA/2J mouse model of glaucoma. |
| Q36678281 | Persistent Borna Disease Virus (BDV) infection activates microglia prior to a detectable loss of granule cells in the hippocampus |
| Q37535952 | Phagocytic glial cells: sculpting synaptic circuits in the developing nervous system |
| Q92501390 | Phagocytosis of full-length Tau oligomers by Actin-remodeling of activated microglia |
| Q39093414 | Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses |
| Q47113551 | Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy |
| Q42263841 | Phospho-Tau Accumulation and Structural Alterations of the Golgi Apparatus of Cortical Pyramidal Neurons in the P301S Tauopathy Mouse Model |
| Q37238262 | Phosphorylated tau: toxic, protective, or none of the above |
| Q26860395 | Physiological and pathological phosphorylation of tau by Cdk5 |
| Q34600121 | Piericidin A aggravates Tau pathology in P301S transgenic mice |
| Q36570476 | Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy |
| Q36380583 | Plasma microRNA biomarkers for detection of mild cognitive impairment |
| Q38996187 | Polymeric alkylpyridinium salts permit intracellular delivery of human Tau in rat hippocampal neurons: requirement of Tau phosphorylation for functional deficits. |
| Q22252516 | Potential benefits of mindfulness-based interventions in mild cognitive impairment and Alzheimer's disease: An interdisciplinary perspective |
| Q47135235 | Practical considerations for choosing a mouse model of Alzheimer's disease |
| Q57817391 | Predict Disease Progression With Reaction Rate Equation Modeling of Multimodal MRI and PET |
| Q39636310 | Preparation and Characterization of Neurotoxic Tau Oligomers |
| Q35546446 | Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation |
| Q30649677 | Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. |
| Q34206962 | Probing the biology of Alzheimer's disease in mice |
| Q61455057 | Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17 |
| Q51901248 | Progranulin expression in the developing and adult murine brain. |
| Q51129031 | Progressive Motor Deficit is Mediated by the Denervation of Neuromuscular Junctions and Axonal Degeneration in Transgenic Mice Expressing Mutant (P301S) Tau Protein. |
| Q35064974 | Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease |
| Q92450973 | Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy |
| Q34285849 | Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer |
| Q31024674 | Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies |
| Q50532471 | Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies. |
| Q34508284 | Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration |
| Q30502900 | Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes |
| Q39849130 | Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells |
| Q39939523 | Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases |
| Q34383788 | Proteopathic tau seeding predicts tauopathy in vivo. |
| Q38859451 | Radiosynthesis and in vivo Evaluation of Carbon-11 (2S)-3-(1H-Indol-3-yl)-2-{[(4-methoxyphenyl)carbamoyl]amino}-N-{[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl}propanamide: An Attempt to Visualize Brain Formyl Peptide Receptors in Mouse Models of Neu |
| Q28487708 | Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice |
| Q30481096 | Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration |
| Q35167904 | Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease |
| Q27303769 | Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain |
| Q36376140 | Recent Advances in the Study of Bipolar/Rod-Shaped Microglia and their Roles in Neurodegeneration |
| Q37448324 | Recent advances in using Drosophila to model neurodegenerative diseases |
| Q58312104 | Recent progress of the Golgi technique and electron microscopy to examine dendritic pathology in Alzheimer’s disease |
| Q48127231 | Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in cultured hippocampal neurons. |
| Q43123500 | Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons |
| Q30669674 | Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies |
| Q47256125 | Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo |
| Q38739859 | Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model |
| Q93197465 | Reduction of the RNA Binding Protein TIA1 Exacerbates Neuroinflammation in Tauopathy |
| Q33856674 | Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation |
| Q46588746 | Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice |
| Q34179654 | Regulation of Tau Pathology by the Microglial Fractalkine Receptor |
| Q38505120 | Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells |
| Q33995490 | Relationship between tau pathology and neuroinflammation in Alzheimer's disease |
| Q34718075 | Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits |
| Q36394952 | Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity |
| Q58795487 | Repositioning Microtubule Stabilizing Drugs for Brain Disorders |
| Q35103703 | Rescue of tau-induced synaptic transmission pathology by paclitaxel |
| Q48959559 | Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model |
| Q33903715 | Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer's Disease-Like Neuropathology in the PS19 and APPSwe Mouse Models of Tauopathy and Amyloidosis. |
| Q35882575 | Role of Liver X Receptor in AD Pathophysiology. |
| Q58780923 | Roles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-β and Tau Pathologies |
| Q61443149 | S-nitrosylation of E3 ubiquitin-protein ligase RNF213 alters non-canonical Wnt/Ca+2 signaling in the P301S mouse model of tauopathy |
| Q46772238 | SIRT1 Regulates Cognitive Performance and Ability of Learning and Memory in Diabetic and Nondiabetic Models |
| Q38543012 | SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons |
| Q34946464 | SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β. |
| Q64939119 | SIRT1: A Novel Way to Target Tau? |
| Q42401404 | SRPK2 phosphorylates tau and mediates the cognitive defects in Alzheimer's disease |
| Q36012200 | Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease |
| Q27324311 | Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes |
| Q58693255 | Senescence-Accelerated Mice P8: A Tool to Study Brain Aging and Alzheimer's Disease in a Mouse Model |
| Q36408405 | Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry |
| Q34195717 | Sevoflurane induces tau phosphorylation and glycogen synthase kinase 3β activation in young mice |
| Q38762142 | Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy |
| Q30611779 | Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice |
| Q36286360 | Soluble forms of tau are toxic in Alzheimer's disease |
| Q45924774 | Spatial learning impairments in PLB1Triple knock-in Alzheimer mice are task-specific and age-dependent. |
| Q33865294 | Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice |
| Q93112033 | Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response |
| Q39379363 | Spreading of Pathology in Alzheimer's Disease |
| Q48524916 | Stimulation of TLR4 Attenuates Alzheimer's Disease-Related Symptoms and Pathology in Tau-Transgenic Mice |
| Q92070007 | Strains of Pathological Protein Aggregates in Neurodegenerative Diseases |
| Q89685555 | Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3β in Alzheimer's disease |
| Q35837935 | Synapses and dendritic spines as pathogenic targets in Alzheimer's disease |
| Q53398002 | Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. |
| Q38684346 | Synaptic activity protects against AD and FTD-like pathology via autophagic-lysosomal degradation. |
| Q37051901 | Synaptic alterations in the rTg4510 mouse model of tauopathy |
| Q98303367 | Synergy between amyloid-β and tau in Alzheimer's disease |
| Q38938489 | Synthesis and evaluation of a new vesamicol analog o-[(11)C]methyl-trans-decalinvesamicol as a PET ligand for the vesicular acetylcholine transporter. |
| Q47923743 | Synthesis and in vitro characterization of a P2X7 radioligand [123I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease |
| Q36617500 | Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy |
| Q99212853 | Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau |
| Q39409037 | T-cell epitope-dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice |
| Q36925612 | TFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits |
| Q64928623 | TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. |
| Q64987725 | TIA1 regulates the generation and response to toxic tau oligomers. |
| Q33749435 | TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy. |
| Q48525796 | TREM2 Ameliorates Neuronal Tau Pathology Through Suppression of Microglial Inflammatory Response |
| Q43140880 | TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy |
| Q37407659 | TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. |
| Q27004724 | Tangles, Toxicity, and Tau Secretion in AD - New Approaches to a Vexing Problem |
| Q39339952 | Targeting Neural Hyperactivity as a Treatment to Stem Progression of Late-Onset Alzheimer's Disease |
| Q33820375 | Targeting psychologic stress signaling pathways in Alzheimer's disease. |
| Q39735894 | Tau Accumulation, Altered Phosphorylation, and Missorting Promote Neurodegeneration in Glaucoma. |
| Q64236054 | Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges |
| Q36241505 | Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? |
| Q42355513 | Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. |
| Q47737194 | Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls. |
| Q37736091 | Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. |
| Q26773154 | Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease |
| Q47123416 | Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. |
| Q37065235 | Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling |
| Q52315334 | Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies? |
| Q33705540 | Tau association with synaptic vesicles causes presynaptic dysfunction |
| Q100431722 | Tau at the interface between neurodegeneration and neuroinflammation |
| Q92501860 | Tau binding protein CAPON induces tau aggregation and neurodegeneration |
| Q46918165 | Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease |
| Q39996419 | Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states |
| Q47623946 | Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons. |
| Q34953869 | Tau in Alzheimer disease and related tauopathies |
| Q55421746 | Tau in neurodegenerative disease. |
| Q98303373 | Tau induces PSD95-neuronal NOS uncoupling and neurovascular dysfunction independent of neurodegeneration |
| Q33559307 | Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo |
| Q64972283 | Tau local structure shields an amyloid-forming motif and controls aggregation propensity. |
| Q37867543 | Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology |
| Q34518577 | Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration |
| Q59789289 | Tau monomer encodes strains |
| Q37307240 | Tau mutations in neurodegenerative diseases |
| Q35574384 | Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. |
| Q41985456 | Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40. |
| Q38107632 | Tau pathology and neurodegeneration |
| Q35985428 | Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections |
| Q42481832 | Tau phosphorylation-associated spine regression does not impair hippocampal-dependent memory in hibernating golden hamsters. |
| Q28070250 | Tau physiology and pathomechanisms in frontotemporal lobar degeneration |
| Q37515094 | Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells |
| Q38998886 | Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. |
| Q91797951 | Tau- but not Aß -pathology enhances NMDAR-dependent depotentiation in AD-mouse models |
| Q55385303 | Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models. |
| Q99711174 | Tau-Mediated Dysregulation of Neuroplasticity and Glial Plasticity |
| Q51019667 | Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. |
| Q29618148 | Tau-mediated neurodegeneration in Alzheimer's disease and related disorders |
| Q88648467 | Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease |
| Q28831067 | Tau-mediated synaptic damage in Alzheimer's disease |
| Q48659268 | Tau-positive nuclear indentations in P301S tauopathy mice. |
| Q26829288 | Tau-tubulin kinase |
| Q33761048 | Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. |
| Q90398264 | Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized With DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins |
| Q42407159 | Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate |
| Q35622023 | Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice |
| Q26825543 | The "quad-partite" synapse: microglia-synapse interactions in the developing and mature CNS |
| Q37261981 | The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease |
| Q42279018 | The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition |
| Q47698987 | The Calcineurin Inhibitor FK506 Prevents Cognitive Impairment by Inhibiting Reactive Astrogliosis in Pilocarpine-Induced Status Epilepticus Rats |
| Q92617140 | The Complex Interactions Between Obesity, Metabolism and the Brain |
| Q92276274 | The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice |
| Q89790628 | The Dual Role of Microglia in the Progression of Alzheimer's Disease |
| Q30780758 | The Dynamics and Turnover of Tau Aggregates in Cultured Cells: INSIGHTS INTO THERAPIES FOR TAUOPATHIES. |
| Q42401543 | The Effects of SIRT1 on Alzheimer's Disease Models |
| Q28119005 | The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy |
| Q37802202 | The Role of Microglia in Synaptic Stripping and Synaptic Degeneration: A Revised Perspective |
| Q39149587 | The Role of Microglia in the Etiology and Evolution of Chronic Traumatic Encephalopathy. |
| Q26771758 | The Role of Oxidative Stress in Neurodegenerative Diseases |
| Q90227644 | The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer's Disease (AD) |
| Q38613647 | The Role of Reelin Signaling in Alzheimer's Disease |
| Q35059866 | The acetylation of tau inhibits its function and promotes pathological tau aggregation |
| Q30490027 | The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. |
| Q89863730 | The behavioural and neuropathologic sexual dimorphism and absence of MIP-3α in tau P301S mouse model of Alzheimer's disease |
| Q57021022 | The cargo receptor SQSTM1 ameliorates neurofibrillary tangle pathology and spreading through selective targeting of pathological MAPT (microtubule associated protein tau) |
| Q34587678 | The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies |
| Q89980820 | The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease |
| Q47284015 | The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy |
| Q28085108 | The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease |
| Q34704881 | The endocannabinoid system and Alzheimer's disease |
| Q92711655 | The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction |
| Q35064995 | The evolving biology of microglia in Alzheimer's disease. |
| Q33485236 | The excitotoxin quinolinic acid induces tau phosphorylation in human neurons |
| Q34506434 | The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes |
| Q47136067 | The fornix provides multiple biomarkers to characterize circuit disruption in a mouse model of Alzheimer's disease |
| Q61772849 | The identity and function of microglia in neurodegeneration |
| Q37053817 | The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence |
| Q38092945 | The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. |
| Q42157266 | The involvement of cholinergic neurons in the spreading of tau pathology. |
| Q35870359 | The many faces of tau |
| Q35875920 | The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice |
| Q37063351 | The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model |
| Q46804886 | The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. |
| Q94585854 | The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study |
| Q37095615 | The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective |
| Q58725042 | The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease |
| Q38365247 | The role of neuroinflammation in dementias |
| Q34104401 | The role of pro-inflammatory S100A9 in Alzheimer's disease amyloid-neuroinflammatory cascade |
| Q37145919 | The role of tau in neurodegeneration |
| Q27005032 | The role of tau in neurodegenerative diseases and its potential as a therapeutic target |
| Q34410713 | The role of tau protein in HIV-associated neurocognitive disorders |
| Q34444298 | The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation |
| Q37164517 | The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus |
| Q37998086 | The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update |
| Q34064026 | Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease |
| Q39164346 | Therapeutic potential of nuclear receptor agonists in Alzheimer's disease |
| Q81527536 | Therapeutic strategies for Alzheimer's disease |
| Q37550818 | Therapeutic strategies for tau mediated neurodegeneration |
| Q47161099 | Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer's disease |
| Q37450674 | Total body 100-mGy X-irradiation does not induce Alzheimer's disease-like pathogenesis or memory impairment in mice |
| Q27336668 | Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. |
| Q57838382 | Transcellular Spreading of Tau in Tauopathies |
| Q90723317 | Transcriptional Networks of Microglia in Alzheimer's Disease and Insights into Pathogenesis |
| Q42060830 | Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response |
| Q36028813 | Transgenic mouse and cell culture models demonstrate a lack of mechanistic connection between endoplasmic reticulum stress and tau dysfunction |
| Q37979824 | Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions |
| Q34675848 | Transmission of tau pathology induced by synthetic preformed tau filaments |
| Q91981508 | Traumatic Brain Injury Induces Tau Aggregation and Spreading |
| Q92931997 | Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model |
| Q57418361 | Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease? |
| Q42042649 | Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations |
| Q35612217 | Truncation of tau at E391 promotes early pathologic changes in transgenic mice |
| Q22241425 | Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease |
| Q35019131 | Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy |
| Q99711176 | Understanding the Pathophysiological Actions of Tau Oligomers: A Critical Review of Current Electrophysiological Approaches |
| Q35604223 | Understanding the kinetic roles of the inducer heparin and of rod-like protofibrils during amyloid fibril formation by Tau protein |
| Q91754836 | VPS35 regulates tau phosphorylation and neuropathology in tauopathy |
| Q37681432 | Vaccination as a therapeutic approach to Alzheimer's disease. |
| Q34810757 | Validation of a rodent model of episodic memory |
| Q43594370 | Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510) |
| Q58720843 | Vulnerability and resilience to Alzheimer's disease: early life conditions modulate neuropathology and determine cognitive reserve |
| Q33999052 | WNT5A signaling contributes to Aβ-induced neuroinflammation and neurotoxicity |
| Q26830542 | Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways |
| Q47870431 | Widespread tau seeding activity at early Braak stages. |
| Q42323269 | Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models |
| Q28833507 | Zebrafish models of Tauopathy |
| Q53392942 | [Tau and cognitive disorders: a role for T lymphocytes]. |
| Q30539812 | mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. |
| Q34753015 | p53 prevents neurodegeneration by regulating synaptic genes. |
| Q44893565 | α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice |
| Q36981528 | β-Amyloid oligomers in aging and Alzheimer's disease |
| Q89766852 | β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates |
| Q92587489 | β-Lactolin, a Whey-Derived Lacto-Tetrapeptide, Prevents Alzheimer's Disease Pathologies and Cognitive Decline |
Search more.